Tag: Nasdaq:MORF
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
Morphic Announces Corporate Highlights and Financial Results for the Full Year...
Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 AbbVie exercised license option to αvβ6 integrin inhibitor program for...